A merged AstraZeneca and BMS could lead Lilly on revenue until about 2030
Neutral
AI Analysis
Summary
AstraZeneca and Bristol Myers Squibb have held merger talks that would create the world's largest drugmaker by revenue, potentially surpassing Eli Lilly until around 2030. The deal would rank among the biggest in pharmaceutical history, though analysts assess it faces significant odds.
Outcome Details
Merger talks reported; would create world's largest drugmaker by revenue
Importance:9/10
Sentiment:
0.00
mergeracquisitionpharmaceutical industry consolidationrevenue leadership
Read the original article
Published by Drug Discovery & Development on August 4, 2026 2:21 AM